Microbot Medical Inc.

NASDAQ:MBOT

Medical - Instruments & Supplies

Healthcare
$0.98 -2.93%

-$0.06 today

Market cap
$65.73M
Beta
1.04
P/E (TTM)
-8.6
EPS (TTM)
-$0.21
52W Low $1.60High $4.67

Volume 0.87M

Average 1.60M

MBOT Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Microbot Medical Inc.NASDAQ: MBOT

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash growth accelerates

Q1 FY2026 net change in cash of $749K rose 634.3% year over year, ahead of the -29.1% change in trailing-twelve-month net change in cash.

Context

  • Net change in cash increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +634.3% holds above the trailing-twelve-month pace of -29.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$749K+126.9% QoQ
Last fiscal yearDec 2025
$810K+25.4% YoY
LTMMar 2026
$1.46M-29.1% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+634.3%——
1 year+25.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
810K USD
Year-over-year change
+25.4%

Net Change in Cash vs competitors

How MBOT compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -29.1% is the 6th highest of 10, against a peer median of +140.5%.
  • Net change in cash amounts to 1387.6% of revenue for MBOT, versus a peer median of 1300.6%.
MBOT Competitors
Net Change in Cash for MBOT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DCGODocGo Inc.LTM Mar 2026$5.67T USD-12837118.8%+54.1%1879098.5%
OVIDOvid Therapeutics Inc.LTM Mar 2026$72.93M USD+856.8%-54.9%1024.0%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$61.31M USD-209.6%-38.7%—
CNTXContext Therapeutics Inc.LTM Mar 2026$34.82M USD-143.9%+26.2%—
VANIVivani Medical, Inc.LTM Mar 2026$6.74M USD+140.5%——
RCELAVITA Medical, Inc.LTM Mar 2026$6.56M USD+215.3%-53.4%9.1%
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$4.12M CAD+178.0%-27.9%—
CLNNClene Inc.LTM Mar 2026$3.89M USD-67.3%-39.8%2905.2%
ZTEKZentek Ltd.LTM Mar 2026CA$2.16M CAD+186.1%—1300.6%
MBOTMicrobot Medical Inc.LTM Mar 2026$1.46M USD-29.1%—1387.6%
Peer median (excluding MBOT) —+140.5%-38.7%1300.6%

Competitors are the stored peer set for MBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(11.31M)(13.17M)(10.74M)(11.44M)(13.14M)
Depreciation & Amortization76K102K106K91K47K
Deferred Income Tax00000
Stock-Based Compensation1.39M1.75M1.39M1.35M1.06M
Change in Working Capital497K(228K)(11K)942K(1.01M)
Accounts Receivables00000
Inventory0000(584K)
Accounts Payables00000
Other Working Capital497K(228K)(11K)942K(424K)
Other Non-Cash Items1.39M(7K)718K234K0
Operating Cash Flow(9.35M)(11.55M)(8.53M)(8.83M)(13.05M)
Capital Expenditures(69K)(84K)(33K)(25K)(60K)
Acquisitions (Net)00000
Purchases of Investments0(3.75M)(10.06M)(5.12M)(82.93M)
Sales of Investments3.27M012.06M6.68M10.6M
Other Investing Activities0(3K)3K00
Investing Cash Flow3.2M(3.84M)1.97M1.54M(72.38M)
Debt Repayment00000
Common Stock Issued04.32M6.56M7.94M86.24M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow04.32M6.56M7.94M86.24M
Effect of Forex Changes00000
Net Change in Cash(6.15M)(11.06M)(2K)646K810K
Free Cash Flow(9.42M)(11.63M)(8.57M)(8.85M)(13.11M)

Microbot Medical Inc.

NASDAQ:MBOT

Intrinsic Alpha fair value

Locked

Current Price

$0.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.